Last reviewed · How we verify
P2Y12 inhibitor de-escalation
P2Y12 inhibitor de-escalation is a P2Y12 inhibitor Small molecule drug developed by Azienda Ospedaliera Universitaria Policlinico "G. Martino". It is currently in Phase 3 development for Acute coronary syndrome, Myocardial infarction, Stroke prevention in atrial fibrillation.
P2Y12 inhibitors block the action of ADP on the P2Y12 receptor, preventing platelet activation and aggregation.
P2Y12 inhibitors block the action of ADP on the P2Y12 receptor, preventing platelet activation and aggregation. Used for Acute coronary syndrome, Myocardial infarction, Stroke prevention in atrial fibrillation.
At a glance
| Generic name | P2Y12 inhibitor de-escalation |
|---|---|
| Sponsor | Azienda Ospedaliera Universitaria Policlinico "G. Martino" |
| Drug class | P2Y12 inhibitor |
| Target | P2Y12 receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
This mechanism is crucial in preventing blood clots and reducing the risk of ischemic events. P2Y12 inhibitors work by inhibiting the binding of ADP to the P2Y12 receptor on platelet surfaces, thereby reducing platelet activation and aggregation.
Approved indications
- Acute coronary syndrome
- Myocardial infarction
- Stroke prevention in atrial fibrillation
Common side effects
- Bleeding
- Thrombocytopenia
- Cerebrovascular accident
Key clinical trials
- Tailoring Bleeding Reduction Approaches in Patients Undergoing PCI (PHASE4)
- The Switching Antiplatelet-9 (SWAP-9) Study (PHASE4)
- Safety and Efficacy of De-escalation Dual Antiplatelet Therapy After BioFreedom™ Stenting in ACS Patients With Moderate-to-high Ischemic and High Bleeding Risk (NA)
- Assessment of an Early De-Escalation to a Low-potency Single Antiplatelet Therapy Guided by Genetics Versus a Systematic High-Potency Single Antiplatelet Therapy to Neutralize Bleeding Complications in Patients With High Bleeding Risk Beyond One Month After an Acute Coronary Syndrome (PHASE3)
- OPT-CAD Score GUIded Dual ANtiplatelet De-esCalation Time (NA)
- Genotype-Guided Abbreviated DAPT Versus Un-Guided De-escalation Therapy in Patients With ACS and HBR (PHASE4)
- Efficacy and Safety of Shortening Dual Antiplatelet Therapy Duration with IVUS Guidance in PCI Patients (NA)
- De-escalating Antiplatelet Therapy to Assess Platelet Reactivity and Outcomes in High Bleeding Risk Patients With Recent ACS (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- P2Y12 inhibitor de-escalation CI brief — competitive landscape report
- P2Y12 inhibitor de-escalation updates RSS · CI watch RSS
- Azienda Ospedaliera Universitaria Policlinico "G. Martino" portfolio CI
Frequently asked questions about P2Y12 inhibitor de-escalation
What is P2Y12 inhibitor de-escalation?
How does P2Y12 inhibitor de-escalation work?
What is P2Y12 inhibitor de-escalation used for?
Who makes P2Y12 inhibitor de-escalation?
What drug class is P2Y12 inhibitor de-escalation in?
What development phase is P2Y12 inhibitor de-escalation in?
What are the side effects of P2Y12 inhibitor de-escalation?
What does P2Y12 inhibitor de-escalation target?
Related
- Drug class: All P2Y12 inhibitor drugs
- Target: All drugs targeting P2Y12 receptor
- Manufacturer: Azienda Ospedaliera Universitaria Policlinico "G. Martino" — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Acute coronary syndrome
- Indication: Drugs for Myocardial infarction
- Indication: Drugs for Stroke prevention in atrial fibrillation